Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 23,504

Document Document Title
WO/2017/177945A1
Uses of a poria cocos extract, a tumulosic acid and/or a pharmaceutically acceptable salt of the tumulosic acid in the preparation of a drug or food, and the drug or the food is used for protecting muscles. The drug is especially used fo...  
WO/2017/178315A1
This invention relates to the use of a composition comprising a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis (strain) 420 (B420), and one or more prebi...  
WO/2017/179707A1
The present invention provides a novel combination for improving frailty or a novel combination for suppressing reduction in skeletal muscle mass. More specifically, the present invention provides a combination for improving frailty or a...  
WO/2017/175181A1
The present invention relates to the quantification of various soluble proteins, including angiogenin in aqueous humor and plasma of patients with AMD. The invention further describes the role of angiogenin in the pathogenesis, progressi...  
WO/2017/170926A1
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...  
WO/2017/173234A1
A method for treating a subject suffering from a motor neuron degenerative disorder is provided herein, the method including: administering to the subject one or more modified adeno-associated virus (AAV) gene delivery vectors packaging ...  
WO/2017/170924A1
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...  
WO/2017/170830A1
Provided is a compound having an MAGL-inhibiting effect, and anticipated to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, amy...  
WO/2017/163076A1
The invention relates to inhibitors of CDK12 (cyclin-dependent kinase 12), and there use in the treatment or prevention of a disorder in a subject caused by the generation of repeat expansion transcripts.  
WO/2017/162870A1
Methods for improving active movement capacity in a subject experiencing muscle impaired or abnormal activity, and software products and computer systems for implementing such methods. A subject having impaired active movement capacity i...  
WO/2017/158190A1
The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, for the treatment of a disease selected fr...  
WO/2017/159380A1
The purpose of the present invention is to provide a method for producing an upper motor neuron from a pluripotent stem cell, and a pluripotent stem cell which can be converted into an upper motor neuron. This method comprises a step for...  
WO/2017/152744A1
The present invention provides a specific protein composition and a method for using the same. The composition is mainly a mixture of human rabies immunoglobulin (HRIG) and human tetanus immunoglobulin (HTIG), wherein the HRIG has an ant...  
WO/2017/152090A3
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes adm...  
WO/2017/150477A1
The purpose of the present invention is to provide a compound having an excellent JAK1-inhibiting activity. The compound according to the present invention has a JAK1-inhibiting activity, and therefore has an immunesuppressing effect, an...  
WO/2017/150228A1
The present invention addresses the problem of providing an efficacious means against muscle atrophy. Provided is a muscle atrophy inhibitor that comprises, as active ingredient(s): (1) one or more proteins selected from the group consis...  
WO/2017/147505A1
Provided are methods of treating muscle and liver disorders, and for increasing mitochondrial mass and/or functionality in a mammalian myocyte and/or hepatocyte.  
WO/2017/144977A1
The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.  
WO/2017/146053A1
Provided are: pharmaceutical composition particles and an orally disintegrating tablet including the same which are capable of achieving both the masking of unpalatable taste and an improvement in elution properties; and a method for pro...  
WO/2017/142054A1
Provided is an artificial nucleoside or an artificial nucleotide which can constitute an artificial oligonucleotide having excellent nuclease resistance. An artificial nucleoside or an artificial nucleotide, which is a compound represent...  
WO/2017/141911A1
The present invention relates to (2E)-N-[2-(dimethylamino)ethyl]-2-hexadecenamide, 2-(diethylamino)ethyl (2E)-2-hexadecenoate, or pharmaceutically acceptable salts thereof. In addition to activating signal transmission via the MAP kinase...  
WO/2017/130151A1
The present invention relates to nucleotides, analogs of mRNA 5'-end (cap) containing sulfur atom at the position 5' of 7-methylguanosine nucleoside. The disclosed compounds are recognized (bound and non-hydrolyzed) by DcpS enzyme (Decap...  
WO/2017/130190A1
This invention provides a novel formulation for effective delivery of a pharmaceutically active ingredient such as a peptide possessing neuroprotective activity. Also provided are methods for treating pertinent clinical implications such...  
WO/2017/131149A1
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...  
WO/2017/132410A1
The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disc...  
WO/2017/131169A1
[Problem] The purpose of the invention is to provide a drug useful in the prophylaxis or treatment of muscle damage. [Solution] The invention relates to a novel pharmaceutical use of an extract from inflamed tissue inoculated with vaccin...  
WO/2017/126645A1
The purpose of the present invention is to provide a composition for inhibiting the migration of endotoxin into blood. According to the present invention, a composition for inhibiting the migration of endotoxin into blood is provided, wh...  
WO/2017/121333A1
Disclosed is a use of a Cistanche tubulosa extract, isoacteoside and/or a pharmaceutically acceptable salt of isoacteoside for the preparation of a drug or a food, wherein the drug or food is used to protect muscles. The drug is especial...  
WO/2017/118968A1
Novel aminoglycosides, represented by Formulae (I), (Ia), (III) and (IIIa), as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical composition...  
WO/2017/119476A1
Provided are: a composition for preventing neurological diseases; use of a material for preventing neurological diseases; and a method for preventing neurological diseases. It has been discovered that a heat-treated product of an animal/...  
WO/2017/113268A1
The present invention relates to a compound for treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and an application of the compound. The invention discloses a compound suppressing a toxicity induced by an rG...  
WO/2017/115789A1
Provided are compositions for recovering and/or ameliorating deterioration of physiological functions due to aging. A cell overexpressing GDF6 protein or an miR-17 family member. A composition for treating aging-related symptoms, said co...  
WO/2017/114339A1
Microencapsulation of β-alanine uses β-alanine as a core material and a mixture of a wall material and an additive as a release material. The additive comprises: a fatty acid-based saturated or unsaturated fatty acid glyceride containi...  
WO/2017/108419A1
Neuregulin-1 (NRG1) or a fragment thereof or vitamin B12 for use in maintaining or increasing muscle function and/or mass in an ageing subject, and/or substantially preventing or reducing muscle wasting in an ageing subject.  
WO/2017/111166A1
According to the present invention, a drug for treating an intracellular TDP-43 content-related disease is developed and provided . In the binding of TDP-43 to a specific mt-tRNA, the binding sites of the respective substances are identi...  
WO/2017/109494A1
The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to fo...  
WO/2017/110705A1
The present invention addresses the problem of developing a drug capable of regrowing synapses, which have been damaged and lost due to a neurodegenerative disease, to thereby provide a medicinal composition for preventing or treating a ...  
WO/2017/106354A1
Compositions and methods useful in treating spinal muscular atrophy are provided. The compositions comprise a recombinant adeno-associated viral vector containing an AAV capsid, e.g., AAVrh.10 capsid, and nucleic acid sequences encoding ...  
WO/2017/101858A1
Disclosed is a method for preparing an extended release dosage form comprising cyclobenzaprine hydrochloride as a main component. The method comprises the following steps: mixing the main component with excipients such as magnesium stear...  
WO/2017/101887A1
A healthcare pharmaceutical preparation having magnesium supplementation and anti-oxidation effects, and a preparation method for the healthcare pharmaceutical preparation. The healthcare pharmaceutical preparation comprises a main effec...  
WO/2017/104180A1
The present invention addresses the problem of providing a composition for enhancing: knee-joint-function improving effects obtained through resistance training without using a training apparatus; and skeletal-muscle-function reinforceme...  
WO/2017/106304A1
Provided herein are peptide-oligomer-conjugates. Also provided herein are methods of treating a central nervous system disorder, a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising admin...  
WO/2017/103851A1
The present invention relates to compounds of Formula (XI) wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hemato...  
WO/2017/103347A1
The invention relates to a combination product including, as active substances, at least lysine and fenugreek or a bioequivalent compound thereof in order to stimulate the appetite. The invention also relates to a cosmetic treatment meth...  
WO/2017/098173A3
The invention relates to the field of medicine. More specifically, the invention relates to the use of compounds, on a patient, in order to prevent and/or treat myopathy, typically muscular dystrophy or cardiomyopathy, or a traumatic inj...  
WO/2017/098731A1
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or prophylactic agent for diseases associated with abnormalities in mitochondrial functions, such...  
WO/2017/097311A1
The present invention relates to Rufinamide(or active derivatives thereof)for use in the treatment of myotonia, such as myotonia congenita, paramyotonia congenita and myotonic dystrophy.The present invention also relates to a combinatori...  
WO/2017/100193A1
The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associate...  
WO/2017/098733A1
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which exhibits an effect of significant inhibition on cell death induced in cells of patients with diseases associated with abnormalities in...  
WO/2017/099237A1
A compound represented by formula (I) and having a property of modulating the activity of an androgen receptor, or a pharmaceutically acceptable salt of the compound. X represents S or O; Z represents (Ra)n-A-(CR13R14)0-1-(CR11R12)0-1-; ...  

Matches 101 - 150 out of 23,504